HomeSectors Biotechnology

Biotechnology

Telix Pharmaceuticals PROSTACT Phase 3 Positions for Global Impact

CSL Limited’s EU Setback and What It Means for CSL Healthcare Growth Australia

CSL Share Price Prediction 2026: Strong Buy?

4DMedical Acquires Contextflow to Build an Immediate European Lung Health Platform

What Do TPG Telecom’s 2026 AGM Changes Mean for Investors?

Ramsay Santé reports strong revenue and EBITDA growth driven by healthcare operations and improved financial performance.

Ramsay Santé Results Show Strong Revenue And EBITDA Growth

Regis Healthcare CEO Search Ends: The Bupa Executive Taking the Wheel at Australia’s Aged Care Giant

Monash IVF Turns Away Soul Patts and Genesis Again – Here’s Why the Board Said No Twice

How IBM’s Quantum Computing Breakthrough Is Transforming Drug Discovery and Accelerating New Treatments

Telix, Regeneron Strike Radiopharma Partnership

COLITCO LLP accepts no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. COLITCO LLP or an associate may receive a commission for funds raised.

↑

Biotechnology

Recent Posts

Categories

Disclaimer

Categories

Trending Posts